Cargando…
Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification
The HER3 receptor is implicated in the progression of various cancers as well as in resistance to several currently used drugs, and is hence a potential target for development of new therapies. We have previously generated Affibody molecules that inhibit heregulin-induced signaling of the HER3 pathw...
Autores principales: | Malm, Magdalena, Kronqvist, Nina, Lindberg, Hanna, Gudmundsdotter, Lindvi, Bass, Tarek, Frejd, Fredrik Y., Höidén-Guthenberg, Ingmarie, Varasteh, Zohreh, Orlova, Anna, Tolmachev, Vladimir, Ståhl, Stefan, Löfblom, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651084/ https://www.ncbi.nlm.nih.gov/pubmed/23675426 http://dx.doi.org/10.1371/journal.pone.0062791 |
Ejemplares similares
-
Correction: Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification
por: Malm, Magdalena, et al.
Publicado: (2013) -
Cellular Effects of HER3-Specific Affibody Molecules
por: Göstring, Lovisa, et al.
Publicado: (2012) -
In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor
por: Seijsing, Johan, et al.
Publicado: (2018) -
Imaging of CAIX-expressing xenografts in vivo using (99m)Tc-HEHEHE-ZCAIX:1 Affibody molecule
por: HONARVAR, HADIS, et al.
Publicado: (2014) -
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis
por: Klint, Susanne, et al.
Publicado: (2023)